Tag Archives: Pfizer

Herbal/Vitamin Supplement Industry – Good or Bad?

Posted on May 29, 2010 by Humair

On some interesting news I read a few months ago, Pfizer’s (a major pharmaceutical company) patent on its impotence drug Viagra has been partially rejected after the U.S. Patent and Trademark Office (USPTO) said it wasn’t different enough from a … Continue reading →

Posted in BioTech/Pharma, Business | Tagged Bayer, Cardioquin, Cephaelis, Cialis, Cinchona, Crystodigin, Digitalis, Dr. Christine Daniel, dysentery, Eli Lilly, Eli Lilly and Company, erectile dysfunction, FDA, Foxglove, heart conditions, horny goat weed, icariin, Ipecacuanha, Lanoxin, Levitra, malaria, Pfizer, pharmaceutical, Plasmodium falciparum, Quin-Release, Quinaglute Dura-tabs, Quinidex Extentabs, Quinine, United States Patent and Trademark Office, USPTO, Viagra, yin yang huo | Leave a comment

Pharma Mega-Mergers: When you can’t innovate, merge

Posted on June 22, 2009 by Humair

In April of 2009, Pfizer agreed to buyout Wyeth for $68 billion; Pfizer’s market cap at that time was just around $100 billion. The following month Merck trumped the Pfizer deal with a $41 billion merger with Schering-Plough. What was … Continue reading →

Posted in BioTech/Pharma, Business | Tagged Biotech, Cozaar, Genentech, Lipitor, Mega-Mergers, Merck, Pfizer, Pharma, Pharmaceuticial, Roche, Schering-Plough, Singulair, Wall Street | Leave a comment

Tag Archives: Pfizer

Herbal/Vitamin Supplement Industry – Good or Bad?

Pharma Mega-Mergers: When you can’t innovate, merge

Blog Archives

Search Blog Archives